![Argen X SE](/common/images/company/EU_ARGX.png)
First and only NMPA-approved subcutaneous injectable FcRn blocker for gMG patients in China Consistent clinical benefit and safety profile of efgartigimod SC compared to IV demonstrated in...
ARDA study data show potential for empasiprubart to drive functional improvement and reduced risk of relapse for multifocal motor neuropathy (MMN) patients ADHERE+ data show durability of...
VYVGART® Hytrulo is first and only neonatal Fc receptor (FcRn) blocker approved to treat chronic inflammatory demyelinating polyneuropathy (CIDP) First novel, precision mechanism of action in...
R&D Day presentations to include recent Phase 2 datasets in Sjogren’s disease (efgartigimod) and multifocal motor neuropathy (empasiprubart) that support advancement to Phase 3 development...
June 4, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases...
$398 million in first quarter global net product sales FDA review ongoing for CIDP sBLA with PDUFA target action date of June 21, 2024 On track to submit filing for pre-filled syringe (PFS) in...
May 7, 2024 – 5:30pm ET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe...
May 7, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases...
May 2, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases...
ADHERE data show VYVGART® Hytrulo has potential to be first advancement for CIDP patients in 30 years Real-world data demonstrate gMG patients able to significantly reduce steroid use over...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 25 | 6.22665006227 | 401.5 | 436.4 | 401.5 | 52215 | 426.59717976 | DE |
4 | 71.5 | 20.1408450704 | 355 | 436.4 | 348.2 | 78301 | 402.20220712 | DE |
12 | 82.6 | 24.0186100611 | 343.9 | 436.4 | 323.4 | 61148 | 371.15792947 | DE |
26 | 80 | 23.088023088 | 346.5 | 436.4 | 322.5 | 60378 | 362.9156492 | DE |
52 | 25 | 6.22665006227 | 401.5 | 494.1 | 271 | 63518 | 398.35952419 | DE |
156 | 170.7 | 66.7318217357 | 255.8 | 494.1 | 224.1 | 65229 | 345.87817721 | DE |
260 | 298.5 | 233.203125 | 128 | 494.1 | 93.05 | 79152 | 261.45152985 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.